Metronidazole

Overview

Metronidazole is a nitroimidazole antibiotic with activity against anaerobic bacteria and protozoa. It is evaluated as a microbiota-modulating agent in hepatobiliary disease, including cholangiocarcinoma (CHOL), by targeting anaerobic gut pathobionts that contribute to gut dysbiosis and LPS-driven hepatic inflammation.

Evidence in the corpus

• Cited among antibiotic-based microbiota-modulation strategies for cholangiocarcinoma adjuvant therapy targeting the gut-liver axis dysbiosis characteristic of CCA; prolonged broad-spectrum antibiotic use (including agents like metronidazole) can paradoxically reduce anti-PD-1 efficacy, requiring careful clinical sequencing PMID:25608663

Resistance mechanisms

Cancer types (linked)

• CHOL — cholangiocarcinoma

Sources

• PMID:25608663

This page was processed by entity-page-writer on 2026-05-14.